The probe into insider trading continues with authorities looking at a number of funds, including SAC Capital, a source tells CNBC.» Read More
NEW YORK, Dec 20- Mathew Martoma, the latest employee of Steven A. Cohen's SAC Capital Advisors to face trial on insider trading charges, lost a bid on Friday to delay his trial, which is scheduled to start on Jan. 6.
NEW YORK, Dec 17- A federal judge on Tuesday rejected former SAC Capital Advisors LP portfolio manager Mathew Martoma's request to dismiss some insider trading charges because they were based on transactions not covered under U.S. securities laws.
NEW YORK, Dec 17- A federal judge on Tuesday rejected former SAC Capital Advisors LP portfolio manager Mathew Martoma's request to dismiss part of the government's insider trading case against him.
A former SAC Capital Advisors trader wants to cite in court some 2012 testimony given by the hedge fund's founder Steven Cohen, claiming it rebuts the government's case.
Filed in U.S. District Court in New York, the Martoma documents showed how extensively investigators questioned Cohen about the trading at the center of the case against Martoma, who was charged in November 2012 with insider trading in what is said to be the most lucrative such U.S. scheme ever.
Attorney Preet Bharara announced at a televised press conference on Nov. 4 that Steven A. Cohen's SAC Capital Advisors would plead guilty to insider trading, two prosecutors stood quietly to his right.
Oct 28- Biogen Idec Inc on Monday reported $286 million in third-quarter sales of its high-profile new multiple sclerosis drug Tecfidera, providing fresh evidence that the medicine is off to an impressive launch and exceeding all expectations.
NEW YORK, Oct 23- Aptalis Pharma Inc, a specialty drugmaker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter said on Wednesday.
After two decades of research, a treatment that slows or reverses the progression of Alzheimer's has proved elusive. The aging of the global population makes the need more urgent.
Wednesday marks 45 days since the end of the second quarter, or as it's known in the financial community, "13F Day." Some of the world's biggest funds report their holdings.
A new development suggests big companies may be getting fed up with Washington. Really fed up.
Who’s best for the markets, Yellen or Summers? Wall Street debates while awaiting Obama’s pick for the next Fed chairman.
Cramer says a trio of recent deals demands attention.
Stocks kicked off the week on a weak note as investors hesitated to jump in ahead of the Federal Reserve meeting and a slew of key economic reports.
U.S. stock index futures ticked lower on Monday, ahead of the Federal Reserve meeting and another heavy week for second quarter earnings.
The Federal Reserve's taper talk may have rattled the financial markets but it has had one notable beneficiary: Mergers and acquisitions.
Some of the names on the move ahead of the open.
Eli Lustgarten of Longbow Research says Caterpillar is probably reaching a bottom and that if mining stabilizes it should be an up year for the stock. The key will be that earnings don't continue downward next year. Ann Duignan of JPMorgan weighs in.
In a highly unusual, 46-page white paper, lawyers for Steve Cohen shoot back at regulators who says he ignored "red flags" at SAC Capital.
U.S. prosecutors do not have enough evidence to file insider trading charges against hedge fund manager Steven A. Cohen before a July deadline, the WSJ reported.